Reagents and methods useful for detecting diseases of the prostate

Abstract

A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as PS116 and transcribed from prostate tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, such as prostate cancer. Also provided are antibodies which specifically bind to PS116-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS116 polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.

1 . A method of detecting the presence of a target PS116 polynucleotide in a test sample, comprising: 
 (a) contacting said test sample with at least one PS116-specific polynucleotide or complement thereof, and    (b) detecting the presence of said target PS116 polynucleotide in the test sample, wherein said PS116-specific polynucleotide has at least 50% identity with a polynucleotide selected from the group consisting of SEQUENCE ID NOS 1-12, and fragments or complements thereof.    
     
     
         2 . The method of  claim 1 , wherein said target PS116 polynucleotide is attached to a solid phase prior to performing step (a).  
     
     
         3 . A method for detecting mRNA of PS116 in a test sample, comprising: 
 (a) performing reverse transcription with at least one primer in order to produce cDNA;    (b) amplifying the cDNA obtained from step (a) using PS116 oligonucleotides as sense and antisense primers to obtain PS116 amplicon; and    (c) detecting the presence of said PS116 amplicon, wherein the PS116 oligonucleotides utilized in steps (a) and (b) have at least 50% identity with a sequence selected from the group consisting of SEQUENCE ID NOS 1-12, and fragments or complements thereof.    
     
     
         4 . The method of  claim 3 , wherein said test sample is reacted with a solid phase prior to performing one of steps (a), (b), or (c).  
     
     
         5 . The method of  claim 3 , wherein said detection step comprises utilizing a detectable label capable of generating a measurable signal.  
     
     
         6 . A method of detecting a target PS116 polynucleotide in a test sample suspected of containing said target, comprising: 
 (a) contacting said test sample with at least one PS116 oligonucleotide as a sense primer and with at least one PS116 oligonucleotide as an anti-sense primer and amplifying to obtain a first stage reaction product;    (b) contacting said first stage reaction product with at least one other PS116 oligonucleotide to obtain a second stage reaction product, with the proviso that the other PS116 oligonucleotide is located 3′ to the PS116 oligonucleotides utilized in step (a) and is complementary to said first stage reaction product; and    (c) detecting said second stage reaction product as an indication of the presence of the target PS116 polynucleotide, wherein the PS116 oligonucleotides utilized in steps (a) and (b) have at least 50% identity with a sequence selected from the group consisting of SEQUENCE ID NOS 1-12, and fragments or complements thereof.    
     
     
         7 . The method of  claim 6 , wherein said test sample is reacted with a solid phase prior to performing one of steps (a), (b), or (c).  
     
     
         8 . The method of  claim 6 , wherein said detection step comprises utilizing a detectable label capable of generating a measurable signal.  
     
     
         9 . The method of  claim 8 , wherein said detectable label is reacted to a solid phase.  
     
     
         10 - 39 . (canceled)  
     
     
         40 . The method of  claim 1 , wherein the presence of said target PS116 polynucleotide in said test sample is indicative of prostate disease.  
     
     
         41 . The method of  claim 3 , wherein the presence of said amplicon is indicative of prostate disease.  
     
     
         42 . The method of  claim 6 , wherein the presence of said second stage reaction product is indicative of prostate disease.  
     
     
         43 - 44 . (canceled)